Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Vigil’s purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. Vigil is utilizing modern neuroscience drug development across multiple therapeutic modalities to deliver precision-based therapies to improve the lives of patients and their families. Vigil went public in January 2022 (NASDAQ: VIGL).
| Headquarters | Cambridge, MA |
| Website | www.vigilneuro.com |
| Pipeline Status | Pre-IND |
| @vigilneuro | |
| Vigil Neuroscience |